{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:02:54Z","timestamp":1792605774575,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Limited data regarding altered linezolid pharmacokinetics in patients with liver cirrhosis are available. The objective of this study was to evaluate the pharmacokinetics, efficacy and safety of linezolid in cirrhotic patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A case\u2013control 1:1 study of patients undergoing linezolid therapeutic drug monitoring was conducted between January 2015 and June 2017. Cases with liver cirrhosis were matched with controls by age, body weight, comorbidities, renal function, and intensive care unit (ICU) admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty-two patients were included, 26 in each group. Patients with Child\u2013Pugh Scores A, B, and C were 1 (3.8%), 13 (50.0%), and 12 (46.2%), respectively. Cases had higher median linezolid trough plasma concentrations than controls [20.6 (17.4) versus 2.7 (11.3); <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001)] and more frequently achieved an optimal pharmacodynamic index [26 (100%) versus 16 (61.5%); <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002]. In addition, potentially toxic concentrations and treatment discontinuation due to overexposure and hematological toxicity were also more frequently seen in cirrhotic patients. Overall clinical cure rate was high (67.4%), and in-hospital mortality was 28.8%. No differences in clinical outcomes were observed between both groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Linezolid showed a high clinical cure rate. Nevertheless, plasma concentrations and treatment discontinuation due to hematological toxicity were higher in cirrhotic patients. Liver cirrhosis may influence linezolid pharmacokinetics and question the use of standard doses. Therapeutic drug monitoring of linezolid would be valuable in these patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000665","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T13:38:45Z","timestamp":1561729125000},"page":"732-739","source":"Crossref","is-referenced-by-count":32,"title":["Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity"],"prefix":"10.1097","volume":"41","author":[{"given":"Sonia","family":"Luque","sequence":"first","affiliation":[{"name":"Pharmacy Department, Parc de Salut Mar;"},{"name":"Institute Hospital del Mar d'Investigacions M\u00e8diques (IMIM);"},{"name":"Universitat Aut\u00f2noma de Barcelona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Mu\u00f1oz-Bermudez","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Parc de Salut Mar;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Echeverr\u00eda-Esnal","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Parc de Salut Mar;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sorli","sequence":"additional","affiliation":[{"name":"Institute Hospital del Mar d'Investigacions M\u00e8diques (IMIM);"},{"name":"Infectious Diseases Department, Parc de Salut Mar;"},{"name":"Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Campillo","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Parc de Salut Mar;"},{"name":"Institute Hospital del Mar d'Investigacions M\u00e8diques (IMIM);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00ednez-Casanova","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Parc de Salut Mar;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gonz\u00e1lez-Colominas","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Parc de Salut Mar;"},{"name":"Universitat Aut\u00f2noma de Barcelona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"\u00c1lvarez-Lerma","sequence":"additional","affiliation":[{"name":"Institute Hospital del Mar d'Investigacions M\u00e8diques (IMIM);"},{"name":"Universitat Aut\u00f2noma de Barcelona;"},{"name":"Intensive Care Unit, Parc de Salut Mar;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Horcajada","sequence":"additional","affiliation":[{"name":"Institute Hospital del Mar d'Investigacions M\u00e8diques (IMIM);"},{"name":"Universitat Aut\u00f2noma de Barcelona;"},{"name":"Infectious Diseases Department, Parc de Salut Mar;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Parc de Salut Mar;"},{"name":"Institute Hospital del Mar d'Investigacions M\u00e8diques (IMIM);"},{"name":"Universitat Aut\u00f2noma de Barcelona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Departments of Intensive Care and Pharmacy, Royal Brisbane and Women's Hospital;"},{"name":"University of Queensland Centre for Clinical Research, The University of Queensland; and"},{"name":"Centre for Anti-infective Translational Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2014.07.001","article-title":"Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections","volume":"44","author":"Luque","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int J Antimicrob Agents."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jinf.2015.06.007","article-title":"Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of gram-positive bacterial infections","volume":"71","author":"Lopez-Garcia","year":"2015","journal-title":"J Infect."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jac\/dku337","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation","volume":"70","author":"Cojutti","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10156-010-0188-8","article-title":"Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery","volume":"17","author":"Ikuta","year":"2011","journal-title":"J Infect Chemother."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.01185-10","article-title":"Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients","volume":"55","author":"Sasaki","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1586\/17474124.2015.1100075","article-title":"New antibiotic strategies in patients with cirrhosis and bacterial infection","volume":"9","author":"Fern\u00e1ndez","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0924-8579(01)00383-1","article-title":"Determination of linezolid in human serum and urine by high-performance liquid chromatography","volume":"18","author":"Borner","year":"2001","journal-title":"Int J Antimicrob Agents."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new simplified acute physiology score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"Le Gall","year":"1993","journal-title":"JAMA."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts","volume":"31","author":"Malinchoc","year":"2000","journal-title":"Hepatology."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc13984","article-title":"Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study","volume":"18","author":"Zoller","year":"2014","journal-title":"Crit Care."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/jac\/dkq281","article-title":"Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?","volume":"65","author":"Legout","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"R24-20230814","first-page":"55","article-title":"Pharmacokinetics of linezolid in patients with liver diseases","volume":"44","author":"Hendershot","year":"1999","journal-title":"J Antimicrob Chemother."},{"key":"R25-20230814","first-page":"1014","article-title":"Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes","volume":"28","author":"Wynalda","year":"2000","journal-title":"Drug Metab Dispos."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.21751","article-title":"Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction","volume":"46","author":"Diamond","year":"2007","journal-title":"Hepatology."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2017.06.023","article-title":"Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study","volume":"50","author":"Wicha","year":"2017","journal-title":"Int J Antimicrob Agents."},{"key":"R28-20230814","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425255.2016.1166204","article-title":"Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones","volume":"12","author":"Cattaneo","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0091270009337947","article-title":"Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients","volume":"49","author":"Abe","year":"2009","journal-title":"J Clin Pharmacol."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/14656566.2016.1182154","article-title":"Risk factors associated with high linezolid trough plasma concentrations","volume":"17","author":"Morata","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425255.2016.1170807","article-title":"Pharmacokinetics of linezolid in critically ill patients","volume":"12","author":"Sazdanovic","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2014.01.012","article-title":"Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight","volume":"79","author":"Niwa","year":"2014","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1128\/AAC.01694-12","article-title":"Risk factors for a low linezolid trough plasma concentration in acute infections","volume":"57","author":"Morata","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.05.009","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients","volume":"48","author":"Dong","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40261-015-0352-0","article-title":"Thrombocytopenia in patients receiving prolonged linezolid may be caused by oxidative stress","volume":"36","author":"Wang","year":"2016","journal-title":"Clin Drug Investig."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s10096-017-2960-5","article-title":"Predictive score of haematological toxicity in patients treated with linezolid","volume":"36","author":"Gonz\u00e1lez-Del Castillo","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1499-3872(15)60379-4","article-title":"High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid","volume":"14","author":"Zhang","year":"2015","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/nep.12346","article-title":"Severe linezolid-induced lactic acidosis in a cirrhosis patient","volume":"20","author":"Hsu","year":"2015","journal-title":"Nephrology (Carlton)."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:19:49Z","timestamp":1692051589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000665","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}